This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schneeberger, P. M.
Right arrow Articles by van Doorn, L.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schneeberger, P. M.
Right arrow Articles by van Doorn, L.-J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 1998, p. 1711-1715, Vol. 36, No. 6
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Hepatitis C Virus Infections in Dialysis Centers in The Netherlands: a National Survey by Serological and Molecular Methods

Peter M. Schneeberger,1,* Ingrid Keur,2 Walter van der Vliet,3 Kitty van Hoek,3 Henk Boswijk,4 Anton M. van Loon,5 Willemien C. van Dijk,6 Robert H. Kauffmann,7 Wim Quint,3 and Leen-Jan van Doorn3

Department of Microbiology, Bosch Medicentrum, Den Bosch,1 Department of Molecular Biology, Diagnostic Center SSDZ, Delft,3 National Institute of Public Health and the Environment, Bilthoven,4 Department of Virology, University Hospital Utrecht, Utrecht,5 Diatel Amsterdam2 and Department of Microbiology, Slotervaart Hospital,6 Amsterdam, and Department of Internal Medicine, Leyenburg Hospital, The Hague,7 The Netherlands

Received 4 August 1997/Returned for modification 23 September 1997/Accepted 25 March 1998

A national survey of hepatitis C virus (HCV) infections among dialysis patients in The Netherlands was performed. The study involved 2,653 patients (2,108 hemodialysis patients and 545 chronic ambulatory peritoneal dialysis [CAPD] patients) from 39 of the 49 dialysis centers in the country. Patient sera were analyzed by both serological and molecular methods. Screening by a third-generation enzyme immunoassay (EIA) yielded 79 reactive sera. The presence of anti-HCV antibodies was confirmed in 70 patients by a line immunoassay. All seropositive samples were tested by reverse transcriptase PCR, and 57 samples were found to contain HCV RNA. Of the nine EIA-positive and line immunoassay-negative or indeterminate samples, four were HCV RNA positive. All seronegative samples were screened for the presence of HCV RNA in pools of five sera. Of 2,576 antibody-negative samples, 6 contained HCV RNA. All antibody-positive and RNA-positive samples were also tested by a second serological assay. The prevalence of HCV infections among Dutch dialysis patients as determined by serology or the presence of HCV RNA was 3% (80 of 2,653), i.e., 3.5% (73 of 2,108) in patients treated on hemodialysis and 1.3% (7 of 545) in patients on CAPD. Of these 80 HCV-infected dialysis patients, 67 (84%) were HCV RNA positive. Serological screening alone would have diagnosed only 70 infected patients. Therefore, antibody screening combined with detection of HCV RNA should be considered as the "gold standard" for diagnosing HCV infection in dialysis patients. The prevalence of HCV-infected patients in Dutch dialysis centers ranged from 0 to 8%, suggesting the existence of local risk factors for acquiring HCV infection. Genotyping analysis by reverse hybridization line probe assay revealed the presence of genotypes 1a (23%), 1b (46%), 2 (3%), 2a (13%), 2b (1%), 3a (7%), and 4a (4%). In four (6%) samples multiple genotypes were detected. The genotype distribution of HCV isolates among Dutch dialysis patients was similar to the distribution among nondialysis patients from the Benelux, except for subtype 1a, which was significantly more prevalent among dialysis patients. In only one center, a high prevalence of an uncommon genotype was suggestive of infection from a common source.


* Corresponding author. Mailing address: Bosch Medicentrum, Dept. of Microbiology, Nieuwstraat 34, 5211 NL, Den Bosch, The Netherlands. Phone: 31 73 6162875. Fax: 31 73 6162958. E-mail: MEDMICRO{at}WORLDONLINE.NL.


Journal of Clinical Microbiology, June 1998, p. 1711-1715, Vol. 36, No. 6
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Perico, N., Cattaneo, D., Bikbov, B., Remuzzi, G. (2009). Hepatitis C Infection and Chronic Renal Diseases. CJASN 4: 207-220 [Abstract] [Full Text]  
  • Ghafur, A., Raza, M., Labbett, W., Chawla, A., Smith, C., Ngui, S. L., Davenport, A., Geretti, A. M. (2007). Travel-associated acquisition of hepatitis C virus infection in patients receiving haemodialysis. Nephrol Dial Transplant 22: 2640-2644 [Abstract] [Full Text]  
  • Terrault, N. A., Adey, D. B. (2007). The Kidney Transplant Recipient with Hepatitis C Infection: Pre- and Posttransplantation Treatment. CJASN 2: 563-575 [Abstract] [Full Text]  
  • Lee, S. C., Antony, A., Lee, N., Leibow, J., Yang, J. Q., Soviero, S., Gutekunst, K., Rosenstraus, M. (2000). Improved Version 2.0 Qualitative and Quantitative AMPLICOR Reverse Transcription-PCR Tests for Hepatitis C Virus RNA: Calibration to International Units, Enhanced Genotype Reactivity, and Performance Characteristics. J. Clin. Microbiol. 38: 4171-4179 [Abstract] [Full Text]  
  • Kleiber, J., Walter, T., Haberhausen, G., Tsang, S., Babiel, R., Rosenstraus, M. (2000). Performance Characteristics of a Quantitative, Homogeneous TaqMan RT-PCR Test for HCV RNA. J. Mol. Diagn. 2: 158-166 [Abstract] [Full Text]